COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,642 Articles (22,913 medRxiv, 8,729 bioRxiv)

Most recent first Previous |  Page 1124: Articles 11231-11240  | Next

A Quantitative Systems Pharmacology Model of the Pathophysiology and Treatment of COVID-19 Predicts Optimal Timing of Pharmacological Interventions
Rao, R., Musante, C. J., Allen, R.
10.1101/2021.12.07.21267277 — Posted: 2021-12-08
Mortality trends and lengths of stay among hospitalized COVID-19 patients in Ontario and Quebec (Canada): a population-based cohort study of the first three epidemic waves
Xia, Y., Ma, H., Mishra, S., Buckeridge, D. L., Brisson, M., Kronfli, N., Sander, B., Chan, A., Verma, A., Ganser, I., Maheu-Giroux, M.
10.1101/2021.12.07.21267416 — Posted: 2021-12-08
Deviations in Predicted COVID-19 cases in the US during early months of 2021 relate to rise in B.1.526 and its family of variants
Nandakishore, P., Lui, M., Prakash, R., Gourneni, S., Sukumaran, R., Berman, J. M., Iyer, S. A., Glorioso, C. A.
10.1101/2021.12.06.21267388 — Posted: 2021-12-08
COVID-19 clusters in schools: frequency, size, and transmission rates from crowdsourced exposure reports
Tupper, P. F., Pai, S., COVID Schools Canada, , Colijn, C.
10.1101/2021.12.07.21267381 — Posted: 2021-12-08
Stochastic simulation of successive waves of COVID-19 in the province of Barcelona.
Bosman, M., Esteve, A., Gabbanelli, L., Jordan, X., Lopez-Gay, A., Manera, M., Martinez, M., Masjuan, P., Mir, L. M., Paradells, J., Pignatelli, A., Riu, I., Vitagliano, V.
10.1101/2021.12.02.21266468 — Posted: 2021-12-08
Dynamic analysis and evaluation of asymptomatic infection in the spread of COVID-19
XU, C. q., Zhang, Z., Huang, X., Cui, J.
10.1101/2021.12.07.21267442 — Posted: 2021-12-08
The influence of new SARS-CoV-2 variant Omicron (B.1.1.529) on vaccine efficacy, its correlation to Delta Variants: a computational approach
Ranjan, P., Neha, , Devi, C., Devar, K. A., Das, P.
10.1101/2021.12.06.471215 — Posted: 2021-12-08
Intranasal immunization with a vaccinia virus vaccine vector expressing pre-fusion stabilized SARS-CoV-2 spike fully protected mice against lethal challenge with the heavily mutated mouse-adapted SARS2-N501YMA30 strain of SARS-CoV-2
Kibler, K. V., Szczerba, M., Lake, D. F., Roeder, A. J., Rahman, M., Hogue, B. G., Wong, L. Y. R., Perlman, S., Li, Y., Jacobs, B. L.
10.1101/2021.12.06.471483 — Posted: 2021-12-08
No evidence of fetal defects or anti-syncytin-1 antibody induction following COVID-19 mRNA vaccination
Lu-Culligan, A., Tabachnikova, A., Tokuyama, M., Lee, H. J., Lucas, C., Silva Monteiro, V., Muenker, M. C., Mohanty, S., Huang, J., Kang, I., Dela Cruz, C., Farhadian, S., Campbell, M., Yildirim, I., Shaw, A., Ko, A., Omer, S., Iwasaki, A.
10.1101/2021.12.07.471539 — Posted: 2021-12-08
Insights on the mutational landscape of the SARS-CoV-2 Omicron variant
Miller, N. L., Clark, T., Raman, R., Sasisekharan, R.
10.1101/2021.12.06.471499 — Posted: 2021-12-08

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).